Eisai's Loss Of Aricept Protection Affects Response To Stock Value
This article was originally published in PharmAsia News
Executive Summary
Eisai is being hit by stock market decisions as would-be investors respond to the company's pending loss of patent protection for its best-seller Alzheimer's disease drug Aricept (donepezil)